Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.51 |
| ▸ | MMP13 | P45452 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 2/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP7 | P09237 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13832841 | 1.00 | GPR119 (0.51) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL13832628 | 1.00 | GPR119 (0.51) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL9068325 | 0.93 | SCN9A (0.49) | GPR119MMP13KMT2AMEN1MMP1 | |
| SCHEMBL344238 | 0.93 | SCN9A (0.49) | GPR119MMP13KMT2AMEN1MMP1 | |
| SCHEMBL344239 | 0.93 | SCN9A (0.49) | GPR119MMP13KMT2AMEN1MMP1 | |
| SCHEMBL216692 | 0.93 | GPR119 (0.58) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL344871 | 0.91 | KMT2A (0.49) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL25315425 | 0.89 | GPR119 (0.54) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL16415290 | 0.89 | GPR119 (0.54) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL17221458 | 0.89 | GPR119 (0.54) | GPR119MMP13KMT2AMEN1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025011623-A1 | CYANOQUINOLINE-TARGETING PROTEIN DEGRADATION MOLECULE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海壹迪生物技术有限公司 | 2025-01-16 | — | — | WO | disclosed |
| CN-119255990-A | Nitrogen-containing five-membered heterocyclic derivative as checkpoint kinase 1 inhibitor and application thereof | 曙方医药 | 2025-01-03 | — | — | CN | disclosed |
| US-20240174662-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | CILAG AG (CH) | 2024-05-30 | — | — | US | disclosed |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| EP-4257591-A2 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| CN-111944012-B | Aromatic amine targeting AR and BET protein degradation chimeric compound and application thereof | 海创药业股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116507613-A | Bispecific antagonists of retinol binding protein 4 which stabilize transthyretin tetramer, their preparation and use in the treatment of common age-related complications | 纽约哥伦比亚大学理事会 | 2023-07-28 | — | — | CN | disclosed |
| CN-115884970-A | Aryl formamide compound and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-3080100-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-3189038-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2202223-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-06-30 | — | — | EP | disclosed |
| US-6239129-B1 | CHARACTERISED BY AN INDOLE RING ON THE AROMATIC MOIETY BY A CYANO GROUP AND ON THE INDOLE NITROGEN BY AN AMINOALKYL CHAIN. GREAT AFFINITY FOR 5-HT2C RECEPTORS, USEFUL FOR DEPRESSION, PANIC ATTACKS, OBSESSIVE-COMPULSIVE DISORDERS, PHOBIAS, | ADIR ET COMPAGNIE (FR) | 2001-05-29 | — | — | US | disclosed |
| US-4997943-A | Bactericides | SANKYO COMPANY LIMITED (JP) | 1991-03-05 | — | — | US | disclosed |
| EP-0241206-A2 | Quinoline-3-carboxylic acid derivatives, their preparation and use | Sankyo Company Limited (JP) | 1987-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | TTR, RBP4, RBP1 | GPR119 110/4885MMP13 3797/4885KMT2A 4352/4885 |
| US-20240174662-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | GPR119 2129/4885MMP13 2499/4885KMT2A 2659/4885 |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RAVER1 | GPR119 743/4885MMP13 3255/4885KMT2A 757/4885 |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | HTR4, MC2R, HTR1D | GPR119 35/4885MMP13 1965/4885KMT2A 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.